UNASSIGNED: A retrospective case series is described, including five patients treated with intracystic peginterferon alfa-2a for cystic CP according to an innovative care protocol. After initial CP cyst aspiration, peginterferon alfa-2a was injected once per week via an Ommaya reservoir for 6 weeks followed by response assessment with MRI.
UNASSIGNED: Patients\' age ranged from 4 to 54 years (four patients <12 years, one adult patient). Intracystic therapy with peginterferon alfa-2a was tolerated well by all five individuals without any major toxicities and resulted in cyst shrinkage in all of the five patients. The importance of a permeability study prior to commencing intracystic therapy became apparent in one patient who suffered from cyst leakage.
UNASSIGNED: Intracystic treatment with peginterferon alfa-2a was found to be a tolerable and efficacious treatment modality in patients with cystic CP. This experience warrants further research with a larger number of patients with measurement of long-term efficacy and safety outcomes.
■描述了回顾性病例系列,包括5例根据创新护理方案接受囊内聚乙二醇干扰素α-2a治疗囊性CP的患者。初次CP囊肿抽吸后,聚乙二醇干扰素α-2a通过Ommaya水库每周注射一次,持续6周,然后用MRI评估反应。
■患者的年龄从4到54岁不等(4名患者<12岁,一名成年患者)。聚乙二醇干扰素α-2a的囊内治疗对所有五名患者的耐受性都很好,没有任何主要毒性,并导致所有五名患者的囊肿缩小。在一名患有囊肿漏的患者中,开始进行囊内治疗之前进行渗透性研究的重要性变得显而易见。
■发现聚乙二醇干扰素α-2a的囊内治疗是囊性CP患者的一种可耐受且有效的治疗方式。这种经验值得对更多患者进行进一步研究,以测量长期疗效和安全性结果。